SGPSpyGlass Pharma, Inc.

Healthcare
$24.70

The financials

SpyGlass Pharma, Inc. by the numbers

The next results filing is expected around Nov 5, 2026, a quarter after the last one.

SpyGlass Pharma, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q1 2025Change
Operating income−$22M−$7.4Mn/a
Net income−$20M−$8.8Mn/a
Diluted EPS−$0.59−$3.96n/a

Biotechnology

The closest names by size in the same industry

Compare peers
ABUS-2.5%
Arbutus Biopharma Corp
ANRO+2.0%
Alto Neuroscience, Inc.
ODTX+0.06%
Odyssey Therapeutics, Inc.
SANA+2.8%
Sana Biotechnology, Inc.
GERN+1.3%
GERON CORP
RIGL+1.6%
RIGEL PHARMACEUTICALS INC